361 related articles for article (PubMed ID: 34987087)
21. ErbB Receptors and Cancer.
Wang Z
Methods Mol Biol; 2017; 1652():3-35. PubMed ID: 28791631
[TBL] [Abstract][Full Text] [Related]
22. Epiregulin: roles in normal physiology and cancer.
Riese DJ; Cullum RL
Semin Cell Dev Biol; 2014 Apr; 28():49-56. PubMed ID: 24631357
[TBL] [Abstract][Full Text] [Related]
23. Molecular modeling of ErbB4/HER4 kinase in the context of the HER4 signaling network helps rationalize the effects of clinically identified HER4 somatic mutations on the cell phenotype.
Telesco SE; Vadigepalli R; Radhakrishnan R
Biotechnol J; 2013 Dec; 8(12):1452-64. PubMed ID: 24318637
[TBL] [Abstract][Full Text] [Related]
24. The receptor tyrosine kinase ERBB4 is expressed in skin keratinocytes and influences epidermal proliferation.
Hoesl C; Röhrl JM; Schneider MR; Dahlhoff M
Biochim Biophys Acta Gen Subj; 2018 Apr; 1862(4):958-966. PubMed ID: 29410073
[TBL] [Abstract][Full Text] [Related]
25. ErbB2 Is Necessary for ErbB4 Ligands to Stimulate Oncogenic Activities in Models of Human Breast Cancer.
Mill CP; Zordan MD; Rothenberg SM; Settleman J; Leary JF; Riese DJ
Genes Cancer; 2011 Aug; 2(8):792-804. PubMed ID: 22393464
[TBL] [Abstract][Full Text] [Related]
26. Localization of phosphorylated ErbB1-4 and heregulin in colorectal cancer.
Mitsui K; Yonezawa M; Tatsuguchi A; Shinji S; Gudis K; Tanaka S; Fujimori S; Sakamoto C
BMC Cancer; 2014 Nov; 14():863. PubMed ID: 25416285
[TBL] [Abstract][Full Text] [Related]
27. Five carboxyl-terminal residues of neuregulin2 are critical for stimulation of signaling by the ErbB4 receptor tyrosine kinase.
Hobbs SS; Cameron EM; Hammer RP; Le AT; Gallo RM; Blommel EN; Coffing SL; Chang H; Riese DJ
Oncogene; 2004 Jan; 23(4):883-93. PubMed ID: 14661053
[TBL] [Abstract][Full Text] [Related]
28. Overexpression of ERBB4 JM-a CYT-1 and CYT-2 isoforms in transgenic mice reveals isoform-specific roles in mammary gland development and carcinogenesis.
Wali VB; Gilmore-Hebert M; Mamillapalli R; Haskins JW; Kurppa KJ; Elenius K; Booth CJ; Stern DF
Breast Cancer Res; 2014 Dec; 16(6):501. PubMed ID: 25516216
[TBL] [Abstract][Full Text] [Related]
29. Quantitative Phosphoproteomics Analysis of ERBB3/ERBB4 Signaling.
Wandinger SK; Lahortiga I; Jacobs K; Klammer M; Jordan N; Elschenbroich S; Parade M; Jacoby E; Linders JT; Brehmer D; Cools J; Daub H
PLoS One; 2016; 11(1):e0146100. PubMed ID: 26745281
[TBL] [Abstract][Full Text] [Related]
30. Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients.
Sassen A; Rochon J; Wild P; Hartmann A; Hofstaedter F; Schwarz S; Brockhoff G
Breast Cancer Res; 2008; 10(1):R2. PubMed ID: 18182100
[TBL] [Abstract][Full Text] [Related]
31. Neuregulin-1 only induces trans-phosphorylation between ErbB receptor heterodimer partners.
Li Z; Mei Y; Liu X; Zhou M
Cell Signal; 2007 Mar; 19(3):466-71. PubMed ID: 16978839
[TBL] [Abstract][Full Text] [Related]
32. Phe45 of NRG2beta is critical for the affinity of NRG2beta for ErbB4 and for potent stimulation of ErbB4 signaling by NRG2beta*.
Hobbs SS; Gallo RM; Riese DJ
Growth Factors; 2005 Dec; 23(4):273-83. PubMed ID: 16338790
[TBL] [Abstract][Full Text] [Related]
33. ErbB2, ErbB3 and ErbB4 expression in urothelial tumors of the upper urinary tract and their prognostic significance.
Galanakis I; Spyropoulos E; Gkialas I; Nomikos A; Souka E; Mitropoulos D
J BUON; 2013; 18(3):653-9. PubMed ID: 24065479
[TBL] [Abstract][Full Text] [Related]
34. HER3 signaling and targeted therapy in cancer.
Mishra R; Patel H; Alanazi S; Yuan L; Garrett JT
Oncol Rev; 2018 Jan; 12(1):355. PubMed ID: 30057690
[TBL] [Abstract][Full Text] [Related]
35. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
Roskoski R
Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
[TBL] [Abstract][Full Text] [Related]
36. AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer.
Hickinson DM; Klinowska T; Speake G; Vincent J; Trigwell C; Anderton J; Beck S; Marshall G; Davenport S; Callis R; Mills E; Grosios K; Smith P; Barlaam B; Wilkinson RW; Ogilvie D
Clin Cancer Res; 2010 Feb; 16(4):1159-69. PubMed ID: 20145185
[TBL] [Abstract][Full Text] [Related]
37. Trophoblast subtype-specific EGFR/ERBB4 expression correlates with cell cycle progression and hyperplasia in complete hydatidiform moles.
Fock V; Plessl K; Fuchs R; Dekan S; Milla SK; Haider S; Fiala C; Knöfler M; Pollheimer J
Hum Reprod; 2015 Apr; 30(4):789-99. PubMed ID: 25740878
[TBL] [Abstract][Full Text] [Related]
38. ErbB4-encoded novel miRNAs act as tumor suppressors by regulating ErbB/PI3K signaling.
Ghaemi Z; Soltani BM; Mowla SJ
Tumour Biol; 2022; 44(1):215-230. PubMed ID: 36442170
[TBL] [Abstract][Full Text] [Related]
39. Expression of the ErbB4 receptor causes reversal regulation of PP2A in the Shc signal transduction pathway in human cancer cells.
Yumoto N; Yu X; Hatakeyama M
Mol Cell Biochem; 2006 Apr; 285(1-2):165-71. PubMed ID: 16477370
[TBL] [Abstract][Full Text] [Related]
40. Progress in Treatment of Non-Small Cell Lung Cancer Harboring HER2 Aberrations.
Ni J; Zhang L
Onco Targets Ther; 2021; 14():4087-4098. PubMed ID: 34262294
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
